DE69434963D1 - Selektiv auf die leber wirkende pharmazeutisch aktive substanz - Google Patents

Selektiv auf die leber wirkende pharmazeutisch aktive substanz

Info

Publication number
DE69434963D1
DE69434963D1 DE69434963T DE69434963T DE69434963D1 DE 69434963 D1 DE69434963 D1 DE 69434963D1 DE 69434963 T DE69434963 T DE 69434963T DE 69434963 T DE69434963 T DE 69434963T DE 69434963 D1 DE69434963 D1 DE 69434963D1
Authority
DE
Germany
Prior art keywords
analogue
insulin
active
daltons
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434963T
Other languages
English (en)
Other versions
DE69434963T2 (de
Inventor
Richard Henry Jones
Fariba Shojaee-Moradi
Peter Henri Sonksen
Dietrich Brandenburg
Achim Schuttler
Heike Eckey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of DE69434963D1 publication Critical patent/DE69434963D1/de
Publication of DE69434963T2 publication Critical patent/DE69434963T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
DE69434963T 1993-08-13 1994-08-15 Selektiv auf die leber wirkende pharmazeutisch aktive substanz Expired - Lifetime DE69434963T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939316895A GB9316895D0 (en) 1993-08-13 1993-08-13 Hepatoselective insulin analogues
GB9316895 1993-08-13
PCT/GB1994/001784 WO1995005187A1 (en) 1993-08-13 1994-08-15 Hepatoselective pharmaceutical actives

Publications (2)

Publication Number Publication Date
DE69434963D1 true DE69434963D1 (de) 2007-06-14
DE69434963T2 DE69434963T2 (de) 2008-01-17

Family

ID=10740471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434963T Expired - Lifetime DE69434963T2 (de) 1993-08-13 1994-08-15 Selektiv auf die leber wirkende pharmazeutisch aktive substanz

Country Status (11)

Country Link
US (3) US5854208A (de)
EP (2) EP1234586A3 (de)
JP (1) JPH10501789A (de)
AT (1) ATE361093T1 (de)
DE (1) DE69434963T2 (de)
DK (1) DK0725648T3 (de)
ES (1) ES2287930T3 (de)
GB (1) GB9316895D0 (de)
HK (1) HK1048058A1 (de)
PT (1) PT725648E (de)
WO (1) WO1995005187A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
JP2002518408A (ja) * 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7582301B1 (en) * 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1299418A1 (de) * 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulinderivat und seine synthese
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2002096935A2 (en) * 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CN1964989B (zh) * 2003-07-25 2012-02-01 康久化学生物技术公司 长效胰岛素衍生物及其方法
ATE433994T1 (de) * 2003-07-25 2009-07-15 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
CA2758460C (en) * 2003-12-16 2014-09-23 Nektar Therapeutics Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
BRPI0811864A2 (pt) * 2007-05-16 2014-11-18 Conjuchem Biotechnologies Inc Derivados de ácido cistéico de peptídeos antivirais
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
MX2010003979A (es) 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
AU2010208319A1 (en) 2009-01-28 2011-08-11 Smartcells, Inc. Crystalline insulin-conjugates
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
US8933207B2 (en) 2010-07-28 2015-01-13 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
EP0242416B1 (de) * 1986-04-22 1991-07-24 Valcor Scientific, Ltd. Verfahren zur Stabilisierung von Proteinen
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
JPH04504858A (ja) * 1989-04-20 1992-08-27 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク 肝臓特異性インシュリン類似体
DK45590D0 (de) * 1990-02-21 1990-02-21 Novo Nordisk As
DK158390D0 (da) * 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
DK33591D0 (de) * 1991-02-27 1991-02-27 Novo Nordisk As
US5268453A (en) * 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
JP2002518408A (ja) 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
EP1299418A1 (de) 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulinderivat und seine synthese

Also Published As

Publication number Publication date
US6063761A (en) 2000-05-16
HK1048058A1 (zh) 2003-03-21
PT725648E (pt) 2007-07-17
ATE361093T1 (de) 2007-05-15
EP0725648B1 (de) 2007-05-02
US5854208A (en) 1998-12-29
EP1234586A3 (de) 2003-04-09
ES2287930T3 (es) 2007-12-16
GB9316895D0 (en) 1993-09-29
USRE39055E1 (en) 2006-04-04
JPH10501789A (ja) 1998-02-17
WO1995005187A1 (en) 1995-02-23
DK0725648T3 (da) 2007-08-20
DE69434963T2 (de) 2008-01-17
EP0725648A1 (de) 1996-08-14
EP1234586A2 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
DK20488A (da) Farmaceutiske praeparater med forlaenget afgivelse
EP1077070A3 (de) Orale Darreichungsform
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
ES2001512A6 (es) Procedimiento para la fabricacion de esteres totales y parciales del acido hialuronico
ATE117548T1 (de) Pharmazeutische zubereitungen zur verhütung von arzneimitteltoleranz.
HK1040631A1 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues.
EP0388220A3 (de) Mittel zur verzögerten Freisetzung von Chlorhexidin
FI935847A0 (fi) L-DOPA-esterkompositioner
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
DE68926115T2 (de) Verfahren zur behandlung von akne
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
GR3032224T3 (en) Therapeutic agent for threatened abortion.
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
KR880008812A (ko) 항균성 동결건조 제제
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
UA29005A (uk) Спосіб лікування трофічних виразок нижніх кінцівок

Legal Events

Date Code Title Description
8364 No opposition during term of opposition